Tissue biomarkers as prognostic variables of cervical cancer

A Gadducci, ME Guerrieri, C Greco - Critical reviews in oncology …, 2013 - Elsevier
The most important prognostic variables of cervical carcinoma are FIGO stage, lymph node
status and clinical-pathological features of primary tumor. Recently, there has been …

Adenocarcinoma of the uterine cervix: pathologic features, treatment options, clinical outcome and prognostic variables

A Gadducci, ME Guerrieri, S Cosio - Critical reviews in oncology …, 2019 - Elsevier
Adenocarcinoma accounts for 10–25% of all cervical cancers, and its relative and absolute
rate has raised over the past decades. Most, but not all the authors, reported that …

Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy

A Gadducci, S Carinelli, ME Guerrieri, GD Aletti - Gynecologic Oncology, 2019 - Elsevier
Placental site trophoblastic tumor [PSTT] and epithelioid trophoblastic tumor [ETT] are the
rarest gestational trophoblastic neoplasias, developing from intermediate trophoblast of the …

Melanoma of the lower genital tract: Prognostic factors and treatment modalities

A Gadducci, S Carinelli, ME Guerrieri, GD Aletti - Gynecologic Oncology, 2018 - Elsevier
Primary melanomas originating from the gynecological tract are rare and aggressive cancers.
The vulva is the most frequent site (70%), followed by vagina and more rarely by cervix. …

Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva

A Gadducci, R Tana, C Barsotti, ME Guerrieri… - Critical reviews in …, 2012 - Elsevier
Several clinical–pathological parameters have been related to survival of patients with invasive
squamous cell carcinoma of the vulva, whereas few studies have investigated the ability …

Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research

A Gadducci, ME Guerrieri - Anticancer Research, 2017 - ar.iiarjournals.org
The presence of tumor infiltrating lymphocytes (TILs) influences the clinical outcome of cancer
patients and immune checkpoint inhibitors (ICPI) have been approved for treating different …

Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A challenging question for gynecologic oncologists

A Gadducci, ME Guerrieri, S Cosio - Critical reviews in oncology …, 2019 - Elsevier
Mature cystic teratomas of the ovary have an incidence of 1.2–14.2 cases per 100.000 people
per year. Malignant transformation occurs in approximately 2% of the cases, and usually …

PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the …

A Gadducci, ME Guerrieri - Critical Reviews in Oncology/Hematology, 2017 - Elsevier
Hereditary epithelial ovarian cancer [EOC] in germline BRCA mutation (gBRCAm) carriers
has a distinct clinical behavior characterized by younger age, high- grade serous histology, …

PARP inhibitors in epithelial ovarian cancer: state of art and perspectives of clinical research

A Gadducci, ME Guerrieri - Anticancer Research, 2016 - ar.iiarjournals.org
Homologous recombination (HR) and base excision repair (BER) are two of the major DNA-repair
pathways. The proteins encoded by breast-related cancer antigen (BRCA) and poly(…

Malignant transformation in mature cystic teratomas of the ovary: case reports and review of the literature

A Gadducci, S Pistolesi, ME Guerrieri… - Anticancer …, 2018 - ar.iiarjournals.org
Malignant transformation occurs in 1.5-2% of mature cystic teratomas (MCT)s of the ovary
and usually consists of squamous cell carcinoma, whereas other malignancies are less …